SynthesisInternal medicine journal2025
Prevalence of vasculitis, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies and spondyloarthritis in Australia: a systematic review and meta-analysis.
Synthesis in Internal medicine journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence of Systemic Lupus Erythematosus in Australia, 2010-2022: A Population-Based Study Using Linked National Administrative Health Data.Arthritis care & research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSystemic autoimmune rheumatic diseases (SARDs), including vasculitis, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), spondyloarthritis (SpA), Sjogrens disease (SjD) and mixed connective tissue disease (MCTD), are rare but associated with substantial morbidity and healthcare burden. Their clinical heterogeneity and diagnostic complexity pose challenges for epidemiological study.
objectiveTo summarise Australian data on the incidence or prevalence of the SARDs listed above.
methodsScientific databases were searched in July 2024. Studies reporting SARD incidence or prevalence in the general Australian population were included. Where three or more studies of the same disease existed within a comparable population, which were not at high risk of bias (Hoy Tool), a random effects model was fitted.
resultsFrom 1357 publications, 58 were included, on: vasculitis (16), SLE (14), RA (10), SSc (nine), IIM (six) and SpA (three), with none on SjD or MCTD identified. Meta-analysis was possible in ANCA-associated vasculitis (AAV) (incidence 10.80 per million person-years), SLE (prevalence 57.86 per 100 000), lupus nephritis (prevalence 11.20 per 100 000, incidence 1.02 per 100 000 person-years), SSc (prevalence 25.58 per 100 000), IIM (incidence 9.96 per million person-years) and inclusion body myositis (prevalence 27.73 per million). Data were limited for paediatric populations and specific at-risk groups (e.g. Australians of Asian heritage).
conclusionAustralia may have above-average prevalence of SLE and SSc and geographic variation in SSc and AAV. Key research gaps include: (1) sparse data for non-AAV vasculitis, RA, SpA, SjD, MCTD and children; (2) limited validated algorithms to identify SARDs in administrative health data; and (3) a need for large-scale spatial studies to detect disease clusters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.